NEW YORK, NY — 3/19/2026 — The Charles H. Revson Foundation is pleased to announce the appointment of Dr. Bradley Bernstein, MD, PhD, to its Board of Directors.
Dr. Bernstein serves as the Chair of Cancer Biology at the Dana-Farber Cancer Institute and Director of the Epigenomics Program at the Broad Institute. His research focuses on epigenetic gene regulation and cancer epigenetics, with groundbreaking contributions to our understanding of the human genome. His work revealed that vast “noncoding” regions of DNA—once considered “junk”—contain critical elements that regulate gene activity. His research has also advanced the field of cancer epigenetics and contributed to the development of new therapies for sarcoma.
In addition to his academic and clinical work, Dr. Bernstein has founded biotechnology companies aimed at translating genomic discoveries into innovative therapies. He is a member of the National Academy of Medicine and a Fellow of the American Association for Cancer Research Academy.
Dr. Bernstein received his B.S. from Yale University and his M.D. and Ph.D. from the University of Washington. He completed a residency at Brigham and Women’s Hospital and postdoctoral research at Harvard University.
Dr. Bernstein’s scientific leadership, pioneering research, and commitment to advancing biomedical innovation will contribute invaluably to the Foundation’s mission of expanding knowledge, advancing democratic values and pursuing the public good.
The Board of Directors looks forward to the insight and energy Dr. Bernstein will bring in his role as Trustee.